|
| |
Alnylam PharmaceuticalsAlnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery that enables the creation of a broad new class of human therapeutics. Using RNAi, Alnylam has built a product platform to develop a deep pipeline of drug products to treat a wide array of important diseases.
Founded by leading scientists who pioneered the discovery of RNAi, Alnylam is developing technology with the potential to specifically and potently silence disease-causing genes. RNA interference is a natural cellular process for selectively turning off the activity of genes by targeting RNA, the key intermediate between DNA and proteins. By harnessing this natural process, Alnylam is developing novel therapeutics that will utilize the natural RNAi mechanism to selectively suppress genes that produce proteins that play harmful roles in disease.
Alnylam is uniquely positioned to leverage the full potential of RNAi for therapeutic applications. Growing from its foundation as the world's first company focused on RNAi therapeutics, the company is built around the leading capabilities of its two operating units, Alnylam Pharmaceuticals of Cambridge, Massachusetts, and Alnylam Europe of Kulmbach, Germany. The company's leading position in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how relating to RNAi. These patents and patent applications broadly cover compositions, methods and uses of small interfering RNAs or siRNAs, the molecules that mediate RNAi. Alnylam's IP estate has been leveraged today with licenses to numerous companies for therapeutic and research market applications. Alnylam has assembled an experienced management team, strong financial resources, and world class collaborators to build a pipeline of RNAi therapeutics using both Direct RNAiTM and Systemic RNAiTM approaches. Alnylam has formed major alliances with Merck, Medtronic and Novartis.
| Contact Details: |
| 300 Third Street, 3rd Floor |
| Cambridge |
| |
| 2142 |
| United States of America |
| Tel: | 617-551-8200 |
| Fax: | 617-551-8101 |
| Email: | |
| WWW: | www.alnylam.com/
|
| |
Recent Publications by Alnylam Pharmaceuticals: |  |
RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy.
We describe the design and characterization of a potent human respiratory... | 6th November, 2009
| Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA.
| Antimicrob Agents Chemother. 2009 Sep;53(9):3952-62. Epub 2009 Jun 8.
DOI Direct Link |
Development of lipidoid-siRNA formulations for systemic delivery to the liver.
RNA interference therapeutics afford the potential to silence target gene... | 30th June, 2009
| Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts 02142, USA.
| Mol Ther. 2009 May;17(5):872-9. Epub 2009 Mar 3.
DOI Direct Link |
Direct CNS Delivery of siRNA Mediates Robust Silencing in Oligodendrocytes.
The most significant challenge remaining in the development of small... | 20th December, 2008
| Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts.
| Oligonucleotides. 2009 Mar;19(1):23-30.
DOI Direct Link |
siRNA and the lung: research tool or therapeutic drug?
Oligonucleotide-based therapeutics have been hailed as 'the next great... | 29th October, 2008
| Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, United
| Curr Opin Pharmacol. 2008 Jun;8(3):280-5. Epub 2008 May 14.
DOI Direct Link |
Delivery vehicles for small interfering RNA in vivo.
RNA interference (RNAi) as a mechanism to selectively silence messenger... | 18th September, 2008
| Alnylam Pharmaceuticals, Cambridge, MA 02142, USA.
| Hum Gene Ther. 2008 Feb;19(2):125-32.
DOI Direct Link |
→View more Alnylam Pharmaceuticals research publications. |
Press Releases on Alnylam Pharmaceuticals:
|
 |
| Isis Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference |
24th November, 2009 |
Isis Pharmaceuticals, Inc. |
CARLSBAD, Calif., Nov. 24 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at
|
| Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals' siRNA Drugs In Multiple Fully Enrolled Clinical Trials |
19th November, 2009 |
Quark Pharmaceuticals, Inc. |
-- Pfizer Inc., which licenses PF-4523655 from Quark, has completed
enrollment in a Phase 2 study of PF-4523655 in patients with diabetic
macular edema (DME). PF-4523655 is
|
| Webcast Alert: Isis Pharmaceuticals Announces Its R&D Webcast Presentation |
19th November, 2009 |
Isis Pharmaceuticals, Inc. |
CARLSBAD, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:
What: Isis Pharmaceuticals' R&D Webcast Presentation
When:
|
| Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA |
11th November, 2009 |
Isis Pharmaceuticals, Inc. |
CARLSBAD, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Genzyme Corporation (Nasdaq: GENZ) announce the following webcast:
What: Isis
|
| Isis Reports Financial Results and Highlights for Third Quarter of 2009 |
5th November, 2009 |
Isis Pharmaceuticals, Inc. |
-- Isis will continue to expand its pipeline by moving at least three new
drugs into development in 2009
Financial Results
On a GAAP basis, Isis reported a loss from operations of $10
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 422 times since April 2007, the link to the organisation's website has been followed 58 times Search for more companies in Cambridge Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Alnylam Pharmaceuticals |
